🔬The Pure Biologics immunotherapy portfolio consists of several projects aimed at developing molecules that activate and direct cells of the immune system to destroy cancer cells.
💊These are new candidates for first-in-class drugs (with new mechanisms of action) taking the form of bispecific antibodies or as antibodies bearing protein fusions which stimulate selected immune cells.
🔥The most advanced projects are PB001, PB003 and PB004 targeting colon cancer, non-small cell lung cancer and triple negative breast cancer.